Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes: 5HT2A

& duration

: Daily dosing

or Depot IM 13 weeks (designed); often persists longer

Use the filters below to narrow your results.

None (1)

Rexulti (1)

Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1)

Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1)

Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1)

0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1)

4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct) (1)

Oral (1)

Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1)

~91 hours (1)

~95% (1)

Limited data; National Pregnancy Registry available (1)

Rx (1)

Showing below up to 1 result in range #1 to #1.

B

Brexpiprazole

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"